653 related articles for article (PubMed ID: 17050778)
1. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
2. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
Fujimori Y; Katsuno K; Ojima K; Nakashima I; Nakano S; Ishikawa-Takemura Y; Kusama H; Isaji M
Eur J Pharmacol; 2009 May; 609(1-3):148-54. PubMed ID: 19281809
[TBL] [Abstract][Full Text] [Related]
3. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
[TBL] [Abstract][Full Text] [Related]
4. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
5. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.
Katsuno K; Fujimori Y; Ishikawa-Takemura Y; Isaji M
Eur J Pharmacol; 2009 Sep; 618(1-3):98-104. PubMed ID: 19615995
[TBL] [Abstract][Full Text] [Related]
7. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
Hussey EK; Clark RV; Amin DM; Kipnes MS; O'Connor-Semmes RL; O'Driscoll EC; Leong J; Murray SC; Dobbins RL; Layko D; Nunez DJ
J Clin Pharmacol; 2010 Jun; 50(6):623-35. PubMed ID: 20056803
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
[TBL] [Abstract][Full Text] [Related]
9. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
[TBL] [Abstract][Full Text] [Related]
10. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
[TBL] [Abstract][Full Text] [Related]
11. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
Rieg T; Masuda T; Gerasimova M; Mayoux E; Platt K; Powell DR; Thomson SC; Koepsell H; Vallon V
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F188-93. PubMed ID: 24226519
[TBL] [Abstract][Full Text] [Related]
12. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
[TBL] [Abstract][Full Text] [Related]
13. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats.
Zhang W; Welihinda A; Mechanic J; Ding H; Zhu L; Lu Y; Deng Z; Sheng Z; Lv B; Chen Y; Roberge JY; Seed B; Wang YX
Pharmacol Res; 2011 Apr; 63(4):284-93. PubMed ID: 21215314
[TBL] [Abstract][Full Text] [Related]
14. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
15. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
[TBL] [Abstract][Full Text] [Related]
16. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
17. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
[TBL] [Abstract][Full Text] [Related]
18. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
[TBL] [Abstract][Full Text] [Related]
20. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
